Bristol-Myers Squibb Company
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Bristol-Myers Squibb Company (BMY). It shows which part of the business is growing — and which one is holding it back.
Revenue by region
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| United States | $26.58B 62.5% | $29.21B 63.0% · +9.9% | $31.50B 68.2% · +7.8% | $31.21B 69.3% · -0.9% | $34.11B 70.6% · +9.3% | $33.28B 69.1% · -2.4% |
| International | – | – | $13.83B 30.0% | $13.10B 29.1% · -5.3% | $13.20B 27.3% · +0.8% | $13.83B 28.7% · +4.8% |
| Other | $631.0M 1.5% | $852.0M 1.8% · +35.0% | $834.0M 1.8% · -2.1% | $699.0M 1.6% · -16.2% | $1.00B 2.1% · +42.5% | $1.09B 2.3% · +9.1% |
| International | $15.31B 36.0% | – | – | – | – | – |
| International | – | $16.32B 35.2% | – | – | – | – |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.